<DOC>
	<DOC>NCT02081300</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.</brief_summary>
	<brief_title>Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Eunuchism</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Antineoplastic Agents, Hormonal</mesh_term>
	<mesh_term>Hormones, Hormone Substitutes, and Hormone Antagonists</mesh_term>
	<criteria>1. Documented diagnosis of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). 2. Serum total testosterone &lt; 300 ng/dL based on 2 consecutive blood samples A subject will not be eligible for study participation if he meets any of the following criteria. 1. History of significant sensitivity or allergy to androgens, castor oil or product excipients. 2. Clinically significant findings in the prestudy examinations. 3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or IPSS score &gt; 19 points. 4. Body mass index (BMI) â‰¥ 38 kg/m2. 5. Clinically significant abnormal laboratory values 6. Positive test result for hepatitis A virus immunoglobulin M (HAVIgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab). 7. History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures. 8. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption. 9. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration. 10. History of stroke or myocardial infarction within the past 5 years. 11. History of, or current or suspected, prostate or breast cancer. 12. History of diagnosed, severe, untreated, obstructive sleep apnea. 13. History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years. 14. History of long QT syndrome or unexplained sudden death in a first degree relative (parent, sibling, or child). 15. Concurrent treatment with medications which may impact the absorption, distribution, metabolism or excretion of testosterone undecanoate (TU) or place the subject at risk for treatment with testosterone. 16. Subject has a partner who is currently pregnant or planning pregnancy during the course of the clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Male hypogonadism</keyword>
	<keyword>Low testosterone</keyword>
	<keyword>LPCN 1021</keyword>
	<keyword>Androgel</keyword>
	<keyword>Testim</keyword>
	<keyword>Testopel</keyword>
	<keyword>Fortesta</keyword>
	<keyword>Axiron.</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Eunuchism</keyword>
	<keyword>Gonadal Disorders</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Testosterone enanthate</keyword>
	<keyword>Testosterone undecanoate</keyword>
	<keyword>Testosterone 17 beta-cypionate</keyword>
	<keyword>Methyltestosterone</keyword>
	<keyword>Androgens</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones, Hormone Substitutes, and Hormone Antagonists</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antineoplastic Agents, Hormonal</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Anabolic Agents</keyword>
</DOC>